Aprea Therapeutics, Inc. · NASDAQ:APRE
Aprea Therapeutics — Investor Presentation (March 2026)
28 slides from Aprea Therapeutics's investor presentation, Mar 30, 2026
Slide 1: Clinical-stage precision medicine oncology company
1 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved A clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers March 2026
Slide 2: Forward-Looking Statements
2 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Forward-Looking Statements Certain information contained in this presentation includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of
Slide 3: One Critical Pathway - Multiple Targets
3 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Aprea Therapeutics (NASDAQ: APRE) One Critical Pathway - Multiple Targets DNA Damage Response (DDR) 1. Ngoi N, et al. Targeting the replication stress response through synthetic lethal strategies in cancer medicine. Trends in Cancer. (2021); 7(
Slide 4: Robust DDR Development Pipeline Milestones 2024-2026
4 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Robust DDR Development Pipeline Milestones 2024-2026 Accomplished and anticipated clinical milestones 2024 2025 2026 H1 H2 H1 H2 H1 H2 ATR ATRN-119 WEE1 APR-1051 RP2D for QD dosing ACESOT-1051: Phase 1 – Monotherapy Dose Escalation Enrolled Fir
Slide 5: Strong Drug Development and Commercial Expertise
5 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Strong Drug Development and Commercial Expertise Experienced team in synthetic lethality and targeted therapy Management Board of Directors Richard Peters, M.D., Ph.D. Chairman of the Board Oren Gilad, Ph.D. President and CEO Jean-Pierre Bizzar
Slide 6: WEE1 Inhibitor: APR-1051 Clinical Proof-Of-Concept
6 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved 6 WEE1 Inhibitor: APR-1051 ACESOT-1051: Clinical Proof-Of-Concept
Slide 7: APR-1051: Next-Generation WEE1 Inhibitor Expanding the Therapeutic Index
7 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved APR-1051: Next–Generation WEE1 Inhibitor Expanding the Therapeutic Index 1. Zentalis Corporate Presentation, January 2026 2. Debio 0123-101, A Phase 1 Trial of Debio 0123 In Combination With Carboplatin In Advanced Solid Tumors: Safety, Pharmac
Slide 8: ACESOT-1051: Phase 1 Study Design
8 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved ACESOT-1051: Phase 1 Study Design * Higher doses permitted if indicated Multi-center, open-label Phase 1 single-agent dose escalation and dose selection optimization Part 1 Dose escalation up to 50 patients RP2D Oral single-agent APR-1051 will
Slide 9: APR-1051 Summary of Duration of Treatment
9 © 2026 Aprea Therapeutics, Inc. All Rights Reserved 50 36 44 21 22 42 44 55 56 43 49 223 36 56 112 178 28 111 85 12 58 63 7 0 50 100 150 200 250 02-001 01-001 01-002 01-003 01-004 02-002 03-002 03-003 03-004 02-003 03-005 01-005 03-007 01-006 03-008 03-006 03-010 01-010 01-008 03-011 03-012 01-011
Slide 10: Treatment-related AEs in Patients Treated with APR-1051
10 © 2026 Aprea Therapeutics, Inc. All Rights Reserved MedDRA Preferred Term APR-1051 All dose levels (N=23) Treatment-related AEsa All Grades n (%) Grade ≥ 3b n (%) Nausea 7 (30.4) 0 (0) Fatigue 4 (17.4) 0 (0) Vomiting 2 (8.7) 0 (0) Alanine aminotransferase increased 1 (4.3) 1 (4.3)c Aspartate amin
Slide 11: Confirmed Partial Response in Patient 01-011
11 © 2026 Aprea Therapeutics, Inc. All Rights Reserved Confirmed Partial Response in Patient 01-011 • 220 mg QD (On Treatment) • Demographics: 63-year-old Black Female Site: MD Anderson Cancer Center Diagnosis: Uterine carcinosarcoma (form of endometrial) Key Mutations: PPP2R1A • Treatment History (
Slide 12: Partial Response in Patient 01-010
12 © 2026 Aprea Therapeutics, Inc. All Rights Reserved Partial Response in Patient 01-010 • 150 mg QD (On treatment) • Demographics: 68-year-old White Female Site: MD Anderson Cancer Center Diagnosis: Uterine Serous Carcinoma (Stage IV, M1) Key Mutations: PPP2R1A • Treatment History (4 prior lines)
Slide 13: APR-1051 (ACESOT-1051): Update March 10th, 2026
13 © 2026 Aprea Therapeutics, Inc. All Rights Reserved APR-1051 (ACESOT-1051): Update March 10th, 2026 • Seven dose levels cleared: 10 mg, 20 mg, 30 mg, 50 mg, 70 mg, 100mg, 150 mg QD • Efficacy update – Two partial responses (PRs) observed, one confirmed thus far • Patient 01-011 (220 mg): Confirme
Slide 14: Disease Control Observed in Early Patient Outcomes
14 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Disease Control Observed in Early Patient Outcomes APR-1051 shows single agent activity in cancer with mutated FBXW7 Clinical Data 100 mg Cohort Patient: 86-year-old Asian Female Diagnosis: Rectal Cancer Key Mutations: FBXW7 (Drives Cyclin E a
Slide 15: Disease Control Observed in Early Patient Outcomes
15 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Clinical Data 70 mg Cohort Disease Control Observed in Early Patient Outcomes Patient: 62-year-old White Male Diagnosis: HPV+ Oropharyngeal Squamous Cell Carcinoma (base of tongue) Key Mutations: P16+ Treatment History: 3 prior lines • Line 1:
Slide 16: A Biomarker Defined Path to Registration
16 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved A Biomarker Defined Path to Registration Data are preliminary from an ongoing dose-escalation study. Responses and stable disease require confirmation in additional patients, and may change as follow-up matures. Safety and efficacy outcomes ma
Slide 17: APR-1051 Demonstrated Preclinical Activity in Combination Across Multiple Cancer Models
17 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved HPV+ Cancer – Collaboration with MD Anderson Ovarian Cancer* UMSCC47 tumor cells OVCAR3 tumor xenograft Tumor Volume (mm3 ) Vehicle Aprea ATRi 30 mg/kg QD Aprea WEE1i 30 mg/kg QD Combination – half dose, 15mg/kg each Days Post Treatment Tumor
Slide 18: Summary
18 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Summary APR-1051 aims to be the first WEE1 inhibitor to translate validated biology into a scalable commercial asset 1 Clinically validated target • WEE1 inhibition has shown promising activity in genomically defined tumors APR-1051 opportunit
Slide 19: APR-1051: Potentially Differentiated WEE1 Inhibitor Pre-Clinical
19 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved 19 APR-1051: Potentially Differentiated WEE1 Inhibitor Pre-Clinical
Slide 20: APR-1051: Potentially Best-in-Class WEE1 Inhibitor
20 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved APR-1051: Potentially Best-in-Class WEE1 Inhibitor Structurally differentiated: high potency, limited off-target inhibition design compared to other molecules AstraZeneca Adavosertib (AZD-1775) Zentalis Azenosertib (ZN-c3) Aprea APR-1051 Undis
Slide 21: APR-1051: Potent Inhibitor of WEE1, Limited PLK Inhibition
21 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved APR-1051: Potentially Best-in-Class WEE1 Inhibitor Potent inhibitor of WEE1 Does not substantially inhibit structurally and functionally related PLK1, PLK2 or PLK3 -10 -9 -8 -7 -6 -5 -4 0 25 50 75 100 125 PLK1 IC50 Determination Log10 [conc] (
Slide 22: PLK1 Inhibition Counteracts Effect of WEE1 Inhibitors
22 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved PLK1 Inhibition Counteracts Effect of WEE1 Inhibitors1 Minimal PLK1 co-inhibition enhances therapeutic window for APR-1051 37 nM 111 nM 333 nM 1 µM 37 nM 111 nM 333 nM 1 µM Phos-H2AX Control (MCM3) NT Phos-CDK1 APR-1051 75 nM GSK-PLKi Control
Slide 23: PLK1 Suppression and Sepsis-Induced Loss of Intestinal Barrier Function
23 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Studies Show PLK1 Suppression is Associated with Sepsis-Induced Loss of Intestinal Barrier Function 1 PLK1 protects against sepsis-induced intestinal barrier dysfunction, Cao et al, Scientific Reports (2018). 2 PLK1 protects intestinal barrier
Slide 24: Intellectual Property Portfolio, Financial Summary & Capitalization, Investment Highlights
24 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved 24 Intellectual Property Portfolio Financial Summary & Capitalization Investment Highlights
Slide 25: Robust Global Intellectual Property Protection
25 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Robust Global Intellectual Property Protection Family 1: Ataxia Telangiectasia and Rad3-Related (ATR) Protein Kinase Inhibitors • Macrocyclic inhibitors of ATR & methods of using them to treat various cancers, filed on Oct. 13th, 2015 • Patent
Slide 26: Financial Summary and Capitalization
26 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Securities Common Equivalents as of March 9, 2026 Preferred Stock (as converted) 15,596 Common Stock (1) 11,452,452 Warrants (2) 16,212,687 Options 840,121 Restricted Stock Units 25,176 Fully Diluted Equivalents 28,546,032 Aprea Therapeutics (
Slide 27: Investment Highlights and Near Term Catalysts
27 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Expected cash runway into Q1 2027 • Achieve near term inflection points and catalysts • Evaluate optimal strategic partnerships Near term catalysts • APR-1051: Q1 2026 Safety/efficacy data ✓ Q3 2026 Complete dose escalation • ATRN-119: October
Slide 28: Aprea Therapeutics
28 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Aprea Therapeutics (NASDAQ: APRE)
Aprea Therapeutics — Investor Presentation (March 2026) on 6ix